Acute heart failure (HF) is commonly encountered in the emergency department and thus, the hospital admissions for worsening HF are increasing. However, the patients presenting with acute HF are heterogenous and complex at high risk of morbidity and mortality. The main goals of treatment for hospitalized patients with HF are to restore euvolemia and to maintain the hemodynamic status without causing adverse events. Currently, the recommendations are usually based on a clinical factor considering the initial systolic blood pressure and other symptoms. Accordingly, initial managements in the hospital generally include diuretics, vasodilators, morphine, and inotropic agents, all of which have been considered as traditional therapies. These agents should mainly increase cardiac output and improve symptoms, and importantly it should improve the clinical outcomes. The aim of this review is to describe the available and new pharmacologic drugs for patients presenting with acute HF.
Blood Pressure ; Cardiac Output ; Diuretics ; Emergencies ; Heart ; Heart Failure ; Hemodynamics ; Humans ; Morphine ; Vasodilator Agents

No abstract available.
Blood Pressure ; *Blood Pressure Monitoring, Ambulatory ; Humans ; *Hypertension

No abstract available.
Atrial Fibrillation* ; Heart Failure*

Increasing rates of coronavirus disease 2019 (COVID-19) vaccination coverage will result in more vaccine-related side effects, including acute myocarditis. In Korea, we present a 24-year-old male with acute myocarditis following COVID-19 vaccination (BNT162b2).His chest pain developed the day after vaccination and cardiac biomarkers were elevated.Echocardiography showed minimal pericardial effusion but normal myocardial contractility.Electrocardiography revealed diffuse ST elevation in lead II, and V2-5. Cardiac magnetic resonance images showed the high signal intensity of T2- short tau inversion recovery image, the high value of T2 mapping sequence, and late gadolinium enhancement in basal inferior and inferolateral wall. It was presumed that COVID-19 mRNA vaccination was probably responsible for acute myocarditis. Clinical course of the patient was favorable and he was discharged without any adverse event.

Increasing rates of coronavirus disease 2019 (COVID-19) vaccination coverage will result in more vaccine-related side effects, including acute myocarditis. In Korea, we present a 24-year-old male with acute myocarditis following COVID-19 vaccination (BNT162b2).His chest pain developed the day after vaccination and cardiac biomarkers were elevated.Echocardiography showed minimal pericardial effusion but normal myocardial contractility.Electrocardiography revealed diffuse ST elevation in lead II, and V2-5. Cardiac magnetic resonance images showed the high signal intensity of T2- short tau inversion recovery image, the high value of T2 mapping sequence, and late gadolinium enhancement in basal inferior and inferolateral wall. It was presumed that COVID-19 mRNA vaccination was probably responsible for acute myocarditis. Clinical course of the patient was favorable and he was discharged without any adverse event.

Constrictive pericarditis is a rare complication after coronary artery bypass grafting In most cases pericardiectomy is required as a definitive treatment. However, there are several types of constrictive pericarditis such as transient cardiac constriction. Some types of constrictive pericarditis can only be managed with medical therapy. We report a 72-year-old female patient who developed subacute transient constrictive pericarditis with persistent left pleural effusion as a result of postcardiac injury syndrome. The patient went through coronary bypass surgery that was successfully treated with postoperative steroid therapy.
Aged ; Constriction ; Coronary Artery Bypass ; Female ; Humans ; Pericardiectomy ; Pericarditis, Constrictive ; Pericardium ; Pleural Effusion

No abstract available.
Extracorporeal Membrane Oxygenation ; Humans ; Tissue Donors

Eisenmenger syndrome is a pulmonary vascular disease in which pulmonary-systemic circulation is connected due to bidirectional shunt caused by congenital heart disease, leading to increased pulmonary vascular resistance and right ventricular failure. Intraoperative management is a challenging task for anesthesiologists when patients with Eisenmenger syndrome undergo non-cardiac surgery, and maintaining both systemic vascular resistance and pulmonary vascular resistance during surgery is critical. In this case, we report that a patient with Eisenmenger syndrome with a humerus fracture successfully underwent open reduction with internal fixation by performing ultrasound guided supraclavicular brachial plexus block and was discharged without complications. When upper limb surgery is performed in patients with Eisenmenger syndrome, ultrasound guided supraclavicular brachial plexus block has fewer hemodynamic changes such as decreased systemic venous resistance and increased pulmonary vascular resistance compared to general anesthesia, and could be a safe anesthetic method in terms of postoperative pain control.

The peri-stent vascular changes after 2nd generation drug-eluting stent (2G DES) implantation have not been fully investigated compare to 1st generation DES (1G DES). From March 2003 to October 2010, patients receiving percutaneous coronary intervention (PCI) with either 1G or 2G DES were retrospectively included. All patients underwent intravascular ultrasound (IVUS) at post-procedure and 8-12 months after PCI. A total of 281 patients (1G DES: 201 patients with 217 lesions and 2G DES: 80 patients with 88 lesions) were enrolled. The incidence of positive peri-stent vascular remodeling (PPVR) and late-acquired incomplete stent apposition (LAISA) were investigated by IVUS images. Major adverse cardiac events (MACE) up to 3 years were also evaluated. The lesion and the stent length were shorter, and the stent size was larger in the 2G DES group. The incidences of PPVR and LAISA were lower in the 2G DES group before and after propensity score matching. However, the incidence of 3-year MACE were not different between the two groups. Independent predictors for PPVR or LAISA were stent length and 1G DES implantation. These results suggested that biocompatible stent system in 2G DES might have reduced peri-stent vascular changes.
Drug-Eluting Stents* ; Humans ; Incidence ; Myocardial Ischemia ; Percutaneous Coronary Intervention ; Propensity Score ; Retrospective Studies ; Stents* ; Ultrasonography*